Infectious Disease

AMA Announces Provisional CPT Codes for Pfizer’s Pediatric COVID-19 Vaccine

October 07, 2021

Read for 1 minute

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact [email protected].

Back to Healio

The AMA has announced preliminary CPT vaccine and administration codes for Pfizer-BioNTech’s pediatric COVID-19 vaccine.

The codes “will be effective for use” when Pfizer-BioNTech’s two-dose vaccine regimen for children receives FDA clearance or emergency clearance, the AMA said in a press release.

The CPT Provisional Vaccine and Administration Codes for the Pfizer-BioNTech Pediatric Vaccine have been released.
Photo source: Adobe Stock

The AMA stated that the product code of the vaccine is as follows:

  • 91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccine, mRNA-LNP, spike protein, free of preservatives, dosage 10 µg / 0.2 ml, reconstituted diluent, tris-sucrose formulation, for intramuscular use.

The codes for vaccine administration are:

  • 0071A Immunization Administration by Intramuscular Injection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus Disease.) [COVID-19]) Vaccine, mRNA-LNP, spike protein, free of preservatives, dosage 10 µg / 0.2 ml, reconstituted diluent, tris-sucrose formulation; first dose; and
  • 0072A Immunization Administration by Intramuscular Injection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus Disease.) [COVID-19]) Vaccine, mRNA-LNP, spike protein, free of preservatives, dosage 10 µg / 0.2 ml, reconstituted diluent, tris-sucrose formulation; second dose.

The New York Times reported today that Pfizer and BioNtech have asked the FDA to provide emergency clearance for their COVID-19 vaccine in children ages 5-11. Last month, the companies released data from a phase 2/3 study that indicated the vaccine was safe and produced “robust” neutralizing antibody titers. The FDA previously announced that it would hold a meeting of the Advisory Committee on Vaccines and Related Biological Products on October 26 to brief “the agency’s decision-making” regarding the vaccine.

References:

AMA Announces CPT Update for Pediatric COVID-19 Vaccine Candidate. https://www.ama-assn.org/press-center/press-releases/ama-announces-cpt-update-pediatric-covid-19-vaccine-candidate. Published October 6, 2021. Accessed October 7, 2021.

FDA will hold advisory committee meetings to discuss approval of booster doses and COVID-19 vaccines for younger children in the event of an emergency. https://www.fda.gov/news-events/press-announcements/fda-hold-advisory-committee-meetings-discuss-emergency-use-authorization-booster-doses-and-covid-19. Published October 1, 2021. Accessed October 7, 2021.

Pfizer is asking the FDA to approve its COVID-19 vaccine for children ages 5-11. https://www.nytimes.com/2021/10/07/us/politics/pfizer-fda-authorization-children-5-11. Published October 7, 2021. Accessed October 7, 2021.

ADD SUBJECT TO EMAIL ALERTS

Receive an email when new articles are published on

Please enter your email address to receive an email when new articles are published on . “data-action =” subscribe “> subscribe

We could not process your request. Please try again later. If this problem persists, please contact [email protected].

Back to Healio

COVID-19 Resource Center

COVID-19 Resource Center

Related Articles